[Perspectives of the use of solcoseryl in the therapy of ischemic encephalopathy].
Two hundreds and forty-three patients with cerebral vascular insufficiency (CVI) who received solcoseril parenterally in doses 2.0 ml daily during 25 days (2 courses in a year) underwent clinical and instrumental examination. The use of solcoseril in combination with hypotensive and antithrormbotic medications exerted a marked positive effect that resulted in regression of neurological symptoms. The increase of effectiveness of solcoseril after the end of treatment course contributed to the stable improvement of patient's state in different stages of disease. A complex treatment, including solcoseril, led to the significant reduction of risk of both disease progression and development of transient ischemic attacks and strokes in patients with CVI compared to the control group receiving only a basic therapy.
Chukanova
E I
EI
Bogolepova
A N
AN
D000183:Actihaemyl / Q000008:administration & dosage / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000453:epidemiology; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology; D018450:Disease Progression; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular
D005343:Fibrinolytic Agents; D000183:Actihaemyl